OrbiMed’s Pfizer PFE Stock Holding History

OrbiMed’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-500,000	Closed	-$12.7M	–	124
2025 Q3	$12.7M	Buy	+500,000	New	+$12.3M	0.3%	67
2025 Q2	–	Sell	-500,000	Closed	-$12.7M	–	112
2025 Q1	$12.7M	Buy	500,000 +250,000	+100%	+$6.54M	0.3%	55
2024 Q4	$6.63M	Buy	+250,000	New	+$6.78M	0.14%	78
2024 Q3	–	Sell	-250,000	Closed	-$7M	–	130
2024 Q2	$7M	Buy	+250,000	New	+$6.88M	0.14%	83
2024 Q1	–	Sell	-500,000	Closed	-$14.4M	–	122
2023 Q4	$14.4M	Buy	+500,000	New	+$15.1M	0.29%	70
2020 Q4	–	Sell	-790,500	Closed	-$27.5M	–	157
2020 Q3	$27.5M	Buy	+790,500	New	+$27.7M	0.35%	74
2020 Q2	–	Sell	-527,000	Closed	-$16.3M	–	147
2020 Q1	$16.3M	Buy	+527,000	New	+$18M	0.27%	74
2013 Q3	–	Sell	-3,412,852	Closed	-$90.7M	–	132
2013 Q2	$90.7M	Buy	+3,412,852	New	+$94.3M	1.92%	19

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

OrbiMed's PFE Position: Q2 2026 in Review

OrbiMed sold out of Pfizer (PFE) in Q2 2026, closing a stake of 1,946,500 shares — an estimated $54.7M sold.

OrbiMed first reported a position in PFE in Q2 2013 and held it in 33 quarters. The position peaked at $202M in Q1 2022. 2,831 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

OrbiMed reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
OrbiMed sold 1,946,500 Pfizer shares in Q2 2026, an estimated $54.7M.
OrbiMed first reported a position in Pfizer in Q2 2013 and held it in 33 quarters.
OrbiMed's Pfizer position peaked at $202M in Q1 2022.
2,831 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.